Bliss GVS Pharma Board Meeting on Oct 29 to Approve Q2 FY27 Results

Bliss GVS Pharma Ltd has announced that its Board of Directors will convene on October 29, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Concurrently, the company has informed about the closure of the trading window for designated persons and their immediate relatives, effective from October 1, 2026, until 48 hours after the financial results are declared. This measure aligns with SEBI regulations on insider trading.